Lv4
570 积分 2024-11-15 加入
Durvalumab versus placebo with chemoradiotherapy for locally advanced cervical cancer (CALLA): a randomised, double-blind, phase 3 trial
2天前
已完结
Evaluating Co‐primary Endpoints Collectively in Clinical Trials
3天前
已完结
Enlonstobart (SG001) plus platinum-based chemotherapy ± bevacizumab for first-line treatment of PD-L1 positive recurrent/metastatic cervical cancer: Safety run-in results of phase III randomized, double-blind, placebo-controlled study
9天前
已完结
Zimberelimab plus lenvatinib in patients with advanced cervical cancer who progressed after prior immune checkpoint inhibitors: A multicenter, single-arm, phase II trial
9天前
已关闭
AK104 combined with concurrent chemoradiotherapy for the treatment of locally advanced cervical cancer: Safety run-in results from the phase III AK104-305 study
9天前
已关闭
Efficacy and Safety of the Anti–PD-L1 mAb Socazolimab for Recurrent or Metastatic Cervical Cancer: a Phase I Dose-Escalation and Expansion Study
9天前
已完结
Evaluation of the overall survival rates in locally advanced cervix cancer patients treated with radiotherapy alone and chemoradiation: A Brazilian experience
14天前
已关闭
Change in Patterns of Failure After Image-Guided Brachytherapy for Cervical Cancer: Analysis From the RetroEMBRACE Study
15天前
已完结
A Randomized Trial of Pelvic Radiation Therapy versus No Further Therapy in Selected Patients with Stage IB Carcinoma of the Cervix after Radical Hysterectomy and Pelvic Lymphadenectomy: A Gynecologic Oncology Group Study
15天前
已完结
Spatiotemporal Immune Determinants of Response to Immune Rechallenge in Advanced Cervical Cancer
15天前
已完结
皖公网安备34019202002308
